EpiCast Report: Osteoarthritis – Epidemiology Forecast to 2026

2017-09-04
Price :
Published : Sep-2017
No. of Pages : 50

EpiCast Report: Osteoarthritis – Epidemiology Forecast to 2026

Summary

Osteoarthritis (OA) is a gradually progressive joint disease that is typically seen in middle-aged to elderly people. According to the American College of Rheumatology (ACR), OA is the most common cause of disability in the elderly. The most commonly affected joints are the knee, hip, hand, and spine. It is characterized by breakdown of the cartilage, bony changes of the joints, deterioration of tendons and ligaments, and various degrees of inflammation of the joint lining.

To forecast the total prevalent cases (radiographic), total prevalent cases (symptomatic), and diagnosed prevalent cases (symptomatic) of hand OA, knee OA, and hip OA in the 7MM, GlobalData epidemiologists selected nationally representative, population-based studies that provided these epidemiological data in the 7MM. GlobalData epidemiologists obtained data for the diagnosed prevalent cases (symptomatic) as well as data for the severity segmentation of the diagnosed prevalent cases (symptomatic) from primary market research. In addition, the forecast is supported by robust, country-specific data that was obtained from various authentic sources such as research articles published in peer-reviewed journals.

In the 7MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases (symptomatic) of hand OA will increase from 17,948,101 cases in 2016 to 20,413,591 cases in 2026 at an annual growth rate (AGR) of 1.37%, the diagnosed prevalent cases (symptomatic) of knee OA will increase from 15,235,201 cases in 2016 to 17,641,626 cases in 2026 at an AGR of 1.58%, and the diagnosed prevalent cases (symptomatic) of hip OA will increase from 3,361,141 cases in 2016 to 3,867,480 cases in 2026 at an AGR of 1.51%.

Scope

– The Osteoarthritis (OA) EpiCast Report provides an overview of the risk factors and global trends of hand OA, knee OA, and hip OA in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
– It includes a 10-year epidemiological forecast for the total prevalent cases (radiographic), total prevalent cases (symptomatic), and diagnosed prevalent cases (symptomatic) of hand OA, knee OA, and hip OA segmented by age (beginning at 18 years and older) and sex in these markets. The diagnosed prevalent cases (symptomatic) of hand OA, knee OA, and hip OA are further segmented by severity using Kellgren-Lawrence (KL) grading into mild (KL = 2), and moderate to severe (KL = 3 to 4).
– The OA epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
– The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The OA EpiCast report will allow you to –
– Develop business strategies by understanding the trends shaping and driving the global OA market.
– Quantify patient populations in the global OA market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for OA therapeutics in each of the markets covered.
– Understand magnitude of OA population by disease severity.

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : GlobalData
More Reports
Title Price Buy Now

Plasma Fractionation Market by Product (IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor), Application (Immunology, Hematology, Critical Care, Rheumatology, Pulmonology), End User (Hospitals & Clinics) – Global Forecast to 2025

 “Growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), and the growing prevalence of respiratory diseases and alpha-1-antitrypsin deficiency (AATD) is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 39.5 billion by 2025 from USD 28.6 billion in 2020, at a CAGR of 6.7% during the forecast period. Growth in the plasma fractionation market is primarily driven by factors such as growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), rising geriatric population, and the growing prevalence of respiratory diseases and alpha-1-ant......
$4950

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (Practice Management, e-Prescribing, PHM, Health Analytics, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User – Global Forecast to 2025

“Government support to increase adoption of EHR solutions is expected to drive the overall growth of the ambulatory EHR market.” The ambulatory EHR market is expected to reach USD 6.8 billion by 2025 from USD 5.2 billion in 2020, at a CAGR of 5.7% during the forecast period of 2020 to 2025. Growth in the global ambulatory EHR market can primarily be attributed to various factors such as government support for the adoption of EHR solutions, increasing number of outpatient care centers, growing patient volume due to the global outbreak of COVID-19, and the need to curtail healthcare costs. On the other hand, market growth is limited to a certain extent due to factors such as reluctance to adopt EHR solutions in developing countries, heavy infrastructure investments, and the high cost ......
$4950

Neisseria meningitidis Infections Global Clinical Trials Review, H2, 2020

Neisseria meningitidis Infections Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Neisseria meningitidis Infections Global Clinical Trials Review, H2, 2020" provides an overview of Neisseria meningitidis Infections Clinical trials scenario. This report provides top line data relating to the clinical trials on Neisseria meningitidis Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using Glob......
$2500

Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H2, 2020

Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H2, 2020" provides an overview of Non-Alcoholic Steatohepatitis (NASH) Clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis (NASH). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generate......
$2500

Oropharyngeal Cancer Global Clinical Trials Review, H2, 2020

Oropharyngeal Cancer Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Oropharyngeal Cancer Global Clinical Trials Review, H2, 2020" provides an overview of Oropharyngeal Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Oropharyngeal Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical tr......
$2500

Actinic (Solar) Keratosis Global Clinical Trials Review, H2, 2020

Actinic (Solar) Keratosis Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Actinic (Solar) Keratosis Global Clinical Trials Review, H2, 2020" provides an overview of Actinic (Solar) Keratosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Actinic (Solar) Keratosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - ......
$2500

Functional (Non Ulcer) Dyspepsia Global Clinical Trials Review, H2, 2020

Functional (Non Ulcer) Dyspepsia Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Functional (Non Ulcer) Dyspepsia Global Clinical Trials Review, H2, 2020" provides an overview of Functional (Non Ulcer) Dyspepsia Clinical trials scenario. This report provides top line data relating to the clinical trials on Functional (Non Ulcer) Dyspepsia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDa......
$2500

Nasopharyngeal Cancer Global Clinical Trials Review, H2, 2020

Nasopharyngeal Cancer Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Nasopharyngeal Cancer Global Clinical Trials Review, H2, 2020" provides an overview of Nasopharyngeal Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Nasopharyngeal Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinica......
$2500

Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H2, 2020

Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H2, 2020" provides an overview of Pre-Diabetes Impaired Glucose Tolerance Clinical trials scenario. This report provides top line data relating to the clinical trials on Pre-Diabetes Impaired Glucose Tolerance. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports ......
$2500

Schizoaffective Disorder Global Clinical Trials Review, H2, 2020

Schizoaffective Disorder Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Schizoaffective Disorder Global Clinical Trials Review, H2, 2020" provides an overview of Schizoaffective Disorder Clinical trials scenario. This report provides top line data relating to the clinical trials on Schizoaffective Disorder. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Phar......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy